Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795770 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL4797013 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL380233 | 0.87 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL380232 | 0.87 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL3978164 | 0.81 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5111282 | 0.81 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL14180276 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3978168 | 0.81 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL6992262 | 0.80 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL4630553 | 0.78 | TACR2 (0.37) | SLC6A2SLC6A4TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378521-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1923391-A1 | Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them. | sanofi-aventis (FR) | 2008-05-21 | — | — | EP | disclosed |
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7223860-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| EP-1688416-A1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | Sanofi-Aventis (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-20060149058-A1 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | disclosed |
| US-7038044-B1 | Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2006-05-02 | — | — | US | disclosed |
| EP-1200417-B1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | disclosed |
| EP-1340754-A1 | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| EP-1140923-B1 | METHOD FOR PREPARING (R)- (+) -3 1- 2-( 4-BENZOYL- 2-(3,4- DIFLUOROPHENYL)MORPHOLIN- 2-YL)ETHYL]- 4-PHENYLPIPERIDIN -4-YL -1,1- DIMETHYLUREA, ITS SALTS SOLVATES AND/OR HYDRATES | SANOFI SYNTHELABO (FR) | 2003-03-05 | — | — | EP | disclosed |
| EP-1156049-A1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2001-11-21 | — | — | EP | disclosed |
| US-6242637-B1 | USED IN TREATMENT INVOLVING THE TACHYKININ SYSTEM, SUCH AS PAIN, ALLERGY AND INFLAMMATION, CIRCULATORY, GASTROINTESTINAL, NEUROLOGICAL, AND NEUROPSYCHIATRIC DISORDERS | SANOFI-SYNTHELABO (FR) | 2001-06-05 | — | — | US | disclosed |
| WO-2001004105-A1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2001-01-18 | — | — | WO | disclosed |
| US-6011154-A | Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 2000-01-04 | — | — | US | disclosed |
| US-5977359-A | Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1999-11-02 | — | — | US | disclosed |
| US-5869663-A | INTERMEDIATES FOR NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1999-02-09 | — | — | US | disclosed |
| US-5780466-A | DISORDERS ASSOCIATED WITH EXCESS TACHYKININS AND ALL NEUROKININ-DEPENDENT DISORDERS; ANALGESICS; RESPIRATORY, GASTROINTESTINAL, UROGENTIAL, IMMUNE, CARDIOVASCULAR AND CNS DISORDERS | SANOFI (FR) | 1998-07-14 | — | — | US | disclosed |
| EP-0807111-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1997-11-19 | — | — | EP | disclosed |
| US-5641777-A | NEUROKININ RECEPTOR ANTAGONIST | SANOFI (FR) | 1997-06-24 | — | — | US | disclosed |
| WO-1996023787-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | ADH1C, ADH1A, ADH5 | SLC6A2 427/4885SLC6A4 524/4885SLC6A3 384/4885 |
| US-20060149058-A1 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | ADH1C, ADH1A, ADH5 | SLC6A2 427/4885SLC6A4 524/4885SLC6A3 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.